Cannabix Technologies to Present at International Association for Chemical Testing (IACT) Conference in Arizona
April 12 2022 - 8:50AM
InvestorsHub NewsWire
501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone: (604)
551-7831
Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix is
developing Marijuana Breathalyzer devices to give law enforcement
and employers a tool to enhance public safety
Vancouver, British Columbia --
April 12, 2022 -- InvestorsHub NewsWire -- Cannabix Technologies
Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix") developer of
marijuana breathalyzer devices for law enforcement and the
workplace reports that it will be presenting at the International
Association for Chemical Testing (IACT) conference in mid-April
2022. Cannabix's Dr. Jared Boock Ph.D.,
will be presenting on THC Breath
Testing Technology and Instrumentation and the Company's marijuana
breathalyzer technologies at the conference workshop session. IACT
is composed of governmental agency personnel involved in chemical
testing related to traffic safety. IACT members are scientific and
criminal justice professionals, including forensic scientists,
regulatory inspectors, and law enforcement personnel with
representatives from a majority of states and international
members. IACT has standing committees to address various areas
including legislation, training, new equipment and procedures and
manufacturers of breath testing equipment.
Version 4.0 THCBA Update
The Company is also pleased to
report that it has shipped new version 4.0 THC Breath Analyzers
(THCBA) to select beta-site locations, replacing the previous
version 3.0. Broader field testing and clinical
testing to establish V4.0 benchmark standards are in development
with this new device. This updated device has new sensor apparatus
design and several related hardware improvements.
The THCBA is a drug screening
device for various markets who are seeking a way to quickly (in
less than 5 minutes), easily and non-invasively test for recent use
of ?9-tetrahydrocannabinol ("THC") - the psychoactive component of
marijuana that causes impairment. The THCBA consists of a handheld
device and protective case which houses a sterilization module,
sample preparation stage, device recovery station and integrated
battery charging system.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a
developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law enforcement
to identify recent marijuana use that
better aligns with impairment. Cannabix devices are in the advanced
prototype and pre-clinical testing stage.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information, contact
the Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that its development of marijuana
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that existing "patent pending" technologies licensed by
the Company will receive patent status by regulatory
authorities. The Company is not currently
selling commercial breathalyzers. Actual results and future events
could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend to update these forward-looking
statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Jan 2025 to Feb 2025
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Feb 2024 to Feb 2025